D. Mccabe

发表

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

Z Domljan, B. Bresnihan, P. Emery, 1998, Arthritis and rheumatism.

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.

H. Genant, B. Bresnihan, Yebin Jiang, 2000, Arthritis and rheumatism.

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.

B. Bresnihan, G. Nuki, D. McCabe, 2002, Arthritis and rheumatism.

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.

Stanley B. Cohen, J. Kremer, M. Weinblatt, 2002, Arthritis and rheumatism.

Efficacy of low-dose celecoxib in patients with acute pain.

B. Schachtel, D. McCabe, M. Berger, 2011, The journal of pain : official journal of the American Pain Society.

Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis

N. Camp, A. Cox, G. Duff, 2005, Genes and Immunity.

Effects of Interleukin-1 Receptor Antagonist in a Slow-Release Hylan Vehicle on Rat Type II Collagen Arthritis

J. Frazier, A. Bendele, T. Mcabee, 1998, Pharmaceutical Research.

The Effectiveness of a Weak Opioid Medication versus a Cyclo-Oxygenase-2 (COX-2) Selective Non-Steroidal Anti-Inflammatory Drug in Treating Flare-Up of Chronic Low-Back Pain: Results from Two Randomized, Double-Blind, 6-Week Studies

D. McCabe, W. Spalding, JB O'Donnell, 2009, The Journal of international medical research.

Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.

J. Frazier, A. Bendele, T. Mcabee, 1999, Arthritis and rheumatism.

Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis.

M. Weisman, L. Moreland, J. Dayer, 2000, The Journal of rheumatology.